Instrumentation Laboratory buys Hemoliance:
This article was originally published in Clinica
Instrumentation Laboratory's parent company, Grupo CH-Werfen, is to buy Hemoliance, a joint venture between Medical Laboratory Automation and Ortho-Clinical Diagnostics, for around $130 million. Hemoliance, which manufactures and distributes haemostasis systems, has revenues of some $80 million. Instrumentation says the combined company will have an enhanced presence in the US market. Hemoliance is a leading supplier of synthetic and recombinant reagents and will bring Instrumentation a solid patent position with its instrument platform, the company says.
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.